This page collects WhisperX intelligence signals tagged #clinical_trials. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Internal SEC filings and whistleblower reports have revealed that a prominent US biotech firm systematically manipulated clinical trial data for a highly touted Alzheimer's drug. Executives allegedly altered Western blot images to fabricate efficacy while suppressing negative safety signals submitted to the FDA. Despit...
Despite federal mandates, a massive loophole in FDA oversight has allowed US pharmaceutical companies and research universities to hide results for thousands of clinical trials. Internal compliance data reveals that the FDA has issued barely a fraction of the required noncompliance notices, effectively shielding the in...
Whispers from within the Chinese pharmaceutical industry point to widespread fraudulent practices involving clinical trials. A prominent domestic firm, reportedly specializing in oncology drugs, is under intense scrutiny for allegedly fabricating patient data and creating 'ghost patients' to inflate trial success rates...
Novocure has reported a significant success for its Tumor Treating Fields (TTFields) therapy in a mid-stage clinical trial for pancreatic cancer. The positive data from this Phase 2 pilot study marks a critical step for the company's technology in one of the most aggressive and difficult-to-treat solid tumors. The tria...
Sanofi's investigational drug lunsekimig has successfully met both its primary and key secondary endpoints in two separate Phase 2 clinical trials, signaling a significant step forward for the biopharma giant's pipeline. The trials evaluated the drug's efficacy and safety in treating patients with asthma and chronic rh...
A targeted oral therapy from Revolution Medicines has delivered a striking survival benefit in a notoriously difficult-to-treat cancer. In a clinical trial, patients with metastatic pancreatic cancer who received the daily pill, daraxonrasib, lived a median of 13.2 months, nearly double the 6.7-month median survival fo...
A targeted pill from Revolution Medicines has delivered a potentially transformative result in metastatic pancreatic cancer, a disease with a notoriously grim prognosis. In a clinical trial, patients taking the daily pill, daraxonrasib, lived a median of 13.2 months, nearly double the 6.7-month median survival for pati...
A Phase 3 trial for advanced pancreatic cancer has delivered a result so significant it could redefine the treatment landscape. Revolution Medicines' experimental oral drug, daraxonrasib, nearly doubled median overall survival compared to standard chemotherapy, extending life from 6.7 months to 13.2 months. This stark ...
Roche is pushing its experimental multiple sclerosis drug fenebrutinib toward regulators, but its path is shadowed by unresolved safety concerns. The Swiss pharmaceutical giant presented new data this week, aiming to prove the drug's efficacy in reducing relapse rates and slowing disability progression. However, the su...